Most Read Articles

Viewssort iconArticle
3075Former Dhhs Secretary, Dr. Louis W. Sullivan, Joins Board Of Directors Of Emergent Biosolutions
1003Emergent Biosolutions Announces Expansion Of Board Of Directors And Appointment Of Dr. Sue Bailey To The Company’s Board Of Dire
928Fuad El-Hibri Ernst & Young Entrepreneur of the Year
795About Fuad El-Hibri on Atlanta Business Chronicle
600Board expands with Election of Fuad El-Hibri
534Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial
472Emergent BioSolutions and Ninebio Sdn. Bhd. AnnounceJoint Venture in Malaysia.
447Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young
423Emergent BioSolutions To Acquire Protein Sciences’ Phase III Recombinant Flu Vaccine Candidate, FluBlok(R), And Related Novel Pl
414New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa
378EMERGENT BIOSOLUTIONS ANNOUNCES EXPANSION OF BOARD OF DIRECTORS AND APPOINTMENT OF DR. SUE BAILEY TO THE COMPANY’S BOARD OF DIRE
371Fuad El-Hibri El-Hibri Peace Education Prize
352U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES REMAINS COMMITTED TO PROCUREMENT OF BIOTHRAX® UNDER CURRENT CONTRACT
349EMERGENT BIOSOLUTIONS ANNOUNCES THE APPOINTMENT OF DENISE LANDRY AS SENIOR VICE PRESIDENT, QUALITY
326Emergent BioSolutions Hosts Biopreparedness Forum for Members of the NATO Parliamentary Assembly
313Nomination Deadline Approaching for 2010 El-Hibri Peace Education Prize
291Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting
279Emergent Biosolutions Announces The Appointment Of Denise Landry As Senior Vice President, Quality
274Bad News Clouds Two Bio Defense Stocks
253Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10
253Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation
249R. Scott Kennedy Awarded the 2008 El-Hibri Peace Education Prize
248October 9, 2008 – Farr Honors Former Santa Cruz Mayor
225Jerome M. Hauer Named To Board Of Directors Of Emergent Biosolutions
221EMERGENT BIOSOLUTIONS’ TYPHOID VACCINE CANDIDATE ACHIEVES ENDPOINTS IN PHASE II CLINICAL STUDY
214Emergent Biosolutions Expands Presence In Germany
213Emergent Biosolutions Acquires Monoclonal Anthrax Product Candidate
213Emergent BioSolutions to Participate in June 2010 Investor Conferences
211Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010
208Emergent Revises Upward 2010 Financial Forecast
205Cornerstone Ceremony Welcomes New Vaccine Production Facility To Michigan
204Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore
203Joe M. Allbaugh, Former Fema Director, Joins Emergent Biosolutions’ Board Of Directors
203500 Most Influential Muslims: Science and Technology
202EMERGENT BIOSOLUTIONS ANTICIPATES 2ND QUARTER BIOTHRAX REVENUES OF APPROXIMATELY $20 MILLION BASED ON ACCELERATED DELIVERY TO DE
200Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine
199Washington Launched Me, But I am Proud to be a Lebanese Dreaming of New Technology – Al Anwar
197Emergent BioSolutions Celebrates Initial Public Offering; CEO To Ring Opening Bell on the NYSE
196Fuad El-Hibri and The National Health Museum
194OXFORD-EMERGENT TUBERCULOSIS CONSORTIUM SIGNS COMMERCIAL LICENSE AGREEMENT WITH PROBIOGEN TO EXPLORE PRODUCTION OF MVA85A TB VAC
194Emergent Biosolutions Announces That Biothrax (Anthrax Vaccine Adsorbed) Receives Market Authorization In India
190Fuad El-Hibri and Healthcare Reform
187Emergent Biosolutions Announces That Department Of Health And Human Services And Department Of Defense Issued Notices Of Intent
186EMERGENT BIOSOLUTIONS SIGNS $448 MILLION THREE YEAR CONTRACT WITH DEPARTMENT OF HEALTH AND HUMAN SERVICES
185Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader
184Fuad El-Hibri on Twine
184Statement By Fuad El-Hibri, Emergent BioSolutions Chairman And Chief Executive Officer, On The Passing of Admiral William Crowe,
183Digg Fuad El-Hibri
182Emergent Biosolutions Announces Management Changes
181Emergent Biosolutions Announces Dr. Stephen Lockhart Joins Company To Lead Commercial Product Development Subsidiary
180Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax
179Fuad El-Hibri on Social Networks
177Maryland Governor Martin O’Malley Leads Ribbon Cutting Ceremony at Emergent’s Baltimore Manufacturing Facility
177Ernst & Young’s Entrepreneur of the Year Fuad El-Hibri
172Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist
170Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Th
170Emergent Biosolutions Anticipates 2Nd Quarter Biothrax Revenues Of Approximately $20 Million Based On Accelerated Delivery To De
169Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments
168Fuad El-Hibri Profiles
165Peace Prize awarded to Center for Nonviolence’s Kennedy
165Fuad El-Hibri is a Washington-Area Success Story
163Emergent BioSolutions to Acquire Trubion Pharmaceuticals
162Fuad El-Hibri’s Linkedin Profile
161Emergent Biosolutions El-Hibri
160Fuad El-Hibri From Wikipedia
160EMERGENT BIOSOLUTIONS ANNOUNCES MANAGEMENT CHANGES
160Emergent Biosolutions Receives Development Contract From Niaid/Barda To Fund Continued Development Of Anthrax Therapeutic
158U.S. Government To Purchase Additional 14.5 Million Doses Of Biothrax® Under New Contract Valued At Up To $404 Million
158Emergrnt Biosultions on Answers.com
157Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule
157Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland
157Fuad El-Hibri on Corridor Inc.
155Fuad El-Hibri and the International Biomedical Research Alliance
154EMERGENT BIOSOLUTIONS ANNOUNCES THAT DEPARTMENT OF HEALTH AND HUMAN SERVICES AND DEPARTMENT OF DEFENSE ISSUED NOTICES OF INTENT
152Rene Moawad Foundation (RMF) USA Holds 14th Annual Washington Gala Dinner
151Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript
151Delegates from European Parliament Express Support for Rapid Development of New TB Vaccine
149Fuad El-Hibri Earnings Call
148Lebanese CEO Sees Opportunity in Current Crisis
148Emergent BioSolutions moves forward with typhoid vaccine
145Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors
143Colman McCarthy to Receive 2010 EL-HIBRI Peace Education Prize
143Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference
142EMERGENT BIOSOLUTIONS ANNOUNCES RESULTS FROM ANNUAL MEETING OF STOCKHOLDERS
142EMERGENT BIOSOLUTIONS INC Profile on AOL
141Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians
140U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES REMAINS COMMITTED TO PROCUREMENT OF BIOTHRAX® UNDER CURRENT CONTRACT
139Nominations Being Accepted Now for 2010 El-Hibri Peace Education Prize
138EMERGENT BIOSOLUTIONS ANNOUNCES DR. STEPHEN LOCKHART JOINS COMPANY TO LEAD COMMERCIAL PRODUCT DEVELOPMENT SUBSIDIARY
137Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
136Emergent Biosolutions Delivers Over 3 Million Doses Of Biothrax® To U.S. Department Of Health And Human Services For Strategic N
135Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocy
133Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals
132Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars
132Emergent Biosolutions Announces Results From Annual Meeting Of Stockholders
127STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE,
126CEO took roundabout path to Emergent
124The El-Hibri Foundation Launches Website
122Fuad El-Hibri Recognized by Vilcek Foundation
121Emergent BioSolutions Observes World TB Day Launches “OETC: Endeavor to End Tuberculosis,” a video to raise public awareness of
121Fuad El-Hibri on Businessweek
121Fuad El-Hibri and the Heifetz International Music Institute
120Emergent BioSolutions to Present Today at Needham & Company Healthcare Conference
119Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
118Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
116Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference
105Emergent BioSolutions Reports Financial Results for First Quarter 2011
104Emergent BioSolutions Reports Financial Results for Full Year 2010
94Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress
87Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax
79Fuad El-Hibri Interviewed by Ricardo Karam
71Emergent BioSolutions' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation
54Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference in London
51FUAD EL-HIBRI TO AWARD 2011 EL-HIBRI PEACE EDUCATION PRIZE TO GENE SHARP
50Fuad El-Hibri Announces Emergent BioSolutionsAward to Supply BioThrax Anthrax Vaccine to U.S. Government
35Fuad El-Hibri and the TAKREEM Achievement Awards
34Fuad El-Hibri on Arabian Business Power 500
8Emergent BioSolutions to Release Fourth Quarter and Full Year 2011 Financial Results and Conduct a Conference Call on March 8, 2